Post-earnings recap
Reported
Thu, Aug 8, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Biocryst Pharmaceuticals reported a larger-than-expected loss per share, which contributed to a significant drop in stock price by 13.08%. The lack of revenue figures and guidance may raise concerns among investors about the company's future performance and profitability. Overall, the results indicate ongoing challenges for the company.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.23 | N/A | -91.67% |
| Revenue | N/A | N/A | N/A |
Management's tone was defensive, highlighting ongoing challenges. They did not offer specific guidance for future performance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.